Alzheimer's Boom or Bust copertina

Alzheimer's Boom or Bust

Alzheimer's Boom or Bust

Ascolta gratuitamente

Vedi i dettagli del titolo

A proposito di questo titolo

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.

email: econrxpodcast@gmail.com

Twitter/Instagram: @EconRx

LinkedIn: www.linkedin.com/company/econrx

Website: https://econrx.libsyn.com/

adbl_web_anon_alc_button_suppression_c
Ancora nessuna recensione